The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria

Fox C M; Bensa S; Bray I; Zajicek J P
January 2004
Journal of Neurology, Neurosurgery & Psychiatry;Jan2004, Vol. 75 Issue 1, p56
Academic Journal
OBJECTIVES: To determine the prevalence of multiple sclerosis in Devon and compare the new McDonald classification guidelines with the Poser criteria currently used. METHODS: All patients known to have multiple sclerosis and alive and resident within the chosen area on 1 June 2001 were included in the study. Seven sources of case ascertainment were used and each patient was classified according to both the Poser criteria and the McDonald guidelines. RESULTS: The prevalence of multiple sclerosis in Devon was 118 per 100,000 (definite and probable cases, Poser criteria) in a population of 341,796, on the prevalence day. The prevalence of definite and possible cases, as classified by the new McDonald guidelines, was slightly lower at 117 per 100,000. Clinical demographics of the prevalent population were similar to those of other studies in the United Kingdom. CONCLUSIONS: This is first survey to use the new recommended guidelines and compare these criteria with the Poser classification. The difficulties encountered with applying the new criteria in research are highlighted, as are the differences between the new and old criteria. This study reports one of the highest prevalences in the south of the UK, adding support for a north-south divide being a step effect rather than a latitudinal gradient.


Related Articles

  • Epidemiology and current treatment of multiple sclerosis in Europe today. Pozzilli, Carlo; Romano, Silvia; Cannoni, Stefania // Journal of Rehabilitation Research & Development;Mar/Apr2002, Vol. 39 Issue 2, p175 

    Discusses the differences in the epidemiology and treatment of multiple sclerosis in Europe. Distribution of multiple sclerosis in Scandinavia; Frequency of the disease in Great Britain; Treatment of acute release; Prevention of relapses and disability; Common treatments used in complementary...

  • Biopsy proven tumefactive multiple sclerosis with concomitant glioma: case report and review of the literature. Golombievski, Esteban E.; McCoyd, Matthew A.; Lee, John M.; Schneck, Michael J. // Frontiers in Neurology;Jul2015, Vol. 6, p1 

    We report a case of pathologically confirmed tumefactive multiple sclerosis (MS) followed shortly thereafter by the diagnosis of an oligoastrocytoma. The complexity of diagnosis and management of concomitant presence of tumefactive MS and glial cell tumors is discussed.

  • Epidemiology — Part II.  // Multiple Sclerosis (13524585);Sep2005 Supplement, Vol. 11, p104 

    Discusses abstracts of studies about the epidemiology of multiple sclerosis, published in the October 2005 issue of the periodical "Multiple Sclerosis". "Prevalence Estimates of Multiple Sclerosis in Nova Scotia," by V. Bhan and colleagues; "Relative Contribution of Incidence and Duration to...

  • Multiple Sclerosis in Newfoundland and Labrador–A Model for Disease Prevalence. Sloka, J. S.; Prvse-Phillips, W. E. M.; Stefanelli, M. // Canadian Journal of Neurological Sciences;Feb2005, Vol. 32 Issue 1, p43 

    Focuses on a model of disease prevalence of multiple sclerosis (MS) in Newfoundland and Labrador. Genetic and environmental contributions to the prevalence of MS; Genetic aspects of MS etiology; Association of interleukin-1Beta and interleukin-1 receptor antagonist genes with disease severity.

  • Epidemiology of Multiple Sclerosis in Western Herzegovina and Herzegovina -- Neretva Canton, Bosnia and Herzegovina. Klupka-Sarić, Inge; Galić, Marijana // Collegium Antropologicum;2010 Supplement 1, Vol. 34, p189 

    The aim of this study was to investigate the selected indicators of multiple sclerosis (MS) in Herzegovina (Western Herzegovina Canton and Herzegovina-Neretva Canton). By using all available health and medical sources in the studied area and using McDonald's criteria, a total of 96 patients were...

  • A second case of Marburg�s variant of multiple sclerosis with vasculitis and extensive demyelination. Elenein, Rania GA; Sharer, Leroy R; Cook, Stuart D; Pachner, Andrew R; Michaels, Jennifer; Hillen, Machteld E // Multiple Sclerosis Journal;Dec2011, Vol. 17 Issue 12, p1531 

    Marburg�s variant of multiple sclerosis is a rapidly progressive and malignant form of multiple sclerosis (MS) that usually leads to severe disability or death within weeks to months without remission. Few cases have been described in the literature since the original description by...

  • Ankilozan Spondilit ve Multipl Sklerozun Beraber Görüldüıü Bir Olgu. Taşitekin, Nurettin; Uzunca, Kaan; Çelik, Yahya; Kurtoğlu, Dilek // Turkish Journal of Physical Medicine & Rehabilitation / Turkiye ;mar2009, Vol. 55 Issue 1, p39 

    Multiple sclerosis and ankylosing spondylitis are two autoimmune diseases in which genetic and environmental factors play an important role in the etiopathogenesis. It has been shown in various studies that multiple sclerosis may be associated with various autoimmune pathological conditions such...

  • Sudden cardiac death in multiple sclerosis caused by active demyelination of the medulla oblongata. Hengstman, G. J. D.; Kusters, B. // Multiple Sclerosis Journal;Sep2011, Vol. 17 Issue 9, p1146 

    Cardiovascular autonomic dysfunction is not uncommon in multiple sclerosis (MS) and is related to the involvement of the vegetative areas of cardiac innervations in the medulla oblongata. It has been suggested that this may contribute to the occurrence of sudden death in MS. In this case report,...

  • Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis: A Retrospective Study. Tenembaum, Silvia N.; Banwell, Brenda; Pohl, Daniela; Krupp, Lauren B.; Boyko, Alexey; Meinel, Michael; Lehr, Lorenz; Rocak, Sanda; Cantogno, Elisabetta Verdun di; Moraga, Margaretha Stam; Ghezzi, Angelo // Journal of Child Neurology;Jul2013, Vol. 28 Issue 7, p849 

    To expand current knowledge, we examined the safety and tolerability of subcutaneous interferon β-1a in patients with pediatric-onset multiple sclerosis. Records from 307 patients who had received at least 1 injection of subcutaneous interferon β-1a for demyelinating events when aged...


Read the Article


Sign out of this library

Other Topics